Increased elimination of paclitaxel by magnesium isoglycyrrhizinate in epithelial ovarian cancer patients treated with paclitaxel plus cisplatin: a pilot clinical study

By Chen Kai   Chen Wan   Chen Xia   Jia Yi   Peng Gui   Chen Li  

European Journal of Drug Metabolism and Pharmacokinetics, Vol. 39, Iss. 1, 2014-03 ,pp. : 25-31

Springer Publishing Company

Access to resources Recommend Favorite

Genetic variations in TP53 binding sites are predictors of clinical outcomes in prostate cancer patients

By Lin Victor   Huang Chao-Yuan   Lee Yung-Chin   Yu Chia-Cheng   Chang Ta-Yuan   Lu Te-Ling   Huang Shu-Pin   Bao Bo-Ying  

Archives of Toxicology, Vol. 88, Iss. 4, 2014-04 ,pp. : 901-911

Springer Publishing Company

Access to resources Recommend Favorite

Eudaimonic well-being and tumor norepinephrine in patients with epithelial ovarian cancer

By  

Cancer, Vol. 121, Iss. 19, 2015-10 ,pp. : 3543-3550

Blackwell Publishing

Access to resources Recommend Favorite

Staging, cytoreduction and chemotherapy improve long-term outcomes in patients with ovarian cancer

By Adis International Limited  

Drugs & Therapy Perspectives, Vol. 22, Iss. 8, 2006-08 ,pp. : 10-13

Adis International

Access to resources Recommend Favorite

Estimation of expectedness: Predictive accuracy of standard therapy outcomes in randomized phase 3 studies in epithelial ovarian cancer

By Castonguay Vincent   Wilson Michelle K.   Diaz-Padilla Ivan   Wang Lisa   Oza Amit M.  

Cancer, Vol. 121, Iss. 3, 2015-02 ,pp. : 413-422

Blackwell Publishing

Access to resources Recommend Favorite